References
- Thomas R, Sanders S, Doust J, et al. Prevalence of attentiondeficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 2015;135:1–8
- Visser S, Danielson M, Bitsko R, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry 2014;53:34–46
- Oshika T. Ocular adverse effects of neuropsychiatric agents. Incidence and management. Drug Saf 1995;12:256–63
- Bartlik B, Harmon G. Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma. Arch Gen Psychiatry 1997;54:188–9
- Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999;37:457–70
- Allen D, Vasavada A. Cataract and surgery for cataract. BMJ 2006;333:128–32
- Spencer RW, Andelman SY. Steroid cataracts. Posterior subcapsular cataract formation in rheumatoid arthritis patients on long term steroid therapy. Arch Ophthalmol 1965;74:38–41
- Van Den Brule J, Degueldre F, Galand A. [Drug-induced cataracts]. Revue Medicale De Liege 1998;53:766–9. [Article in French]
- Lu CK, Kuang TM, Chou JCK. Methylphenidate (Ritalin)-associated cataract and glaucoma. J Chinese Med Assoc 2006;69:589–90
- Feldman HM, Michael I. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 2014;370:838–46
- Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 2008;237:1–14
- American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007–22
- National Collaborating Centre For Mental Health. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. London: NICE; 2008
- Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003;5:833–41
- Faraone SV, Short EJ, Biederman J, et al. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int J Neuropsychopharmacol 2002;5:121–9
- Clavenna A, Maurizio B. Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Arch Dis Childhood 2014;99:866–872
- Shahzad S, Suleman MI, Shahab H, et al. Cataract occurrence with antipsychotic drugs. Psychosomatics 2002;43:354–9
- Kirwan JF, Ventler L, Stulting AA, Murdoch IE. LOCS III examination at the slit lamp, do settings matter? Ophthalmic Epidemiol 2010;10:259–66.
- Chylack LT, Jr Wolfe JK, Singer DM, et al. The lens opacities classification system III. The longitudinal study of cataract study group. Arch Ophthalmol 1993;111:831–6
- James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther 2007;23:403–20